AERI - Aerie Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Show:
Income statement
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
30/12/2018
30/12/2017
30/12/2016
30/12/2015
Total revenue
59,687
24,181
0
0
0
Cost of revenue
3,526
641
-
-
0
Gross profit
56,161
23,540
-
-
0
Operating expenses
Research development
87,076
86,123
72,078
52,394
44,451
Selling general and administrative
134,822
120,614
73,615
44,478
30,635
Total operating expenses
245,640
233,282
145,693
96,872
75,086
Operating income or loss
-189,479
-209,742
-145,693
-96,872
-75,086
Interest expense
9,760
2,531
2,368
2,537
2,493
Total other income/expenses net
450
-23,722
-555
543
3,355
Income before tax
-196,065
-232,566
-146,863
-98,866
-74,224
Income tax expense
-90
3
-1,758
193
139
Income from continuing operations
-195,975
-232,569
-145,105
-99,059
-74,363
Net income
-195,975
-232,569
-145,105
-99,059
-74,363
Net income available to common shareholders
-195,975
-232,569
-145,105
-99,059
-74,363
Reported EPS
Basic
-
-5.58
-4.11
-3.40
-2.88
Diluted
-
-5.58
-4.11
-3.40
-2.88
Weighted average shares outstanding
Basic
-
41,664
35,324
29,136
25,781
Diluted
-
41,664
35,324
29,136
25,781
EBITDA
-
-227,593
-143,085
-95,359
-71,479
By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more